Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant TACE plus tislelizumab in locally advanced gastric adenocarcinoma
ChiCTR2000037759Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in gastric adenocarcinoma, sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Pathological complete response rate (pCR), Pathological response rate (pRR) and 3 more. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2000037759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037759.